Belyntic is a company headquartered in Germany. Brouky records 1 investor associated with the company.
Belyntic develops novel immunotherapies and vaccines that harness patients' T cell responses to fight infectious diseases and cancer using their proprietary T-Fender platform based on synthetic long peptides and AI-powered design.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.